CN112603991A - 一种用于修复宫颈糜烂的凝胶及其制备方法 - Google Patents
一种用于修复宫颈糜烂的凝胶及其制备方法 Download PDFInfo
- Publication number
- CN112603991A CN112603991A CN202011522876.4A CN202011522876A CN112603991A CN 112603991 A CN112603991 A CN 112603991A CN 202011522876 A CN202011522876 A CN 202011522876A CN 112603991 A CN112603991 A CN 112603991A
- Authority
- CN
- China
- Prior art keywords
- silicon dioxide
- gel
- collagen
- dioxide powder
- cervical erosion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003628 erosive effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title abstract description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 52
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 36
- 102000008186 Collagen Human genes 0.000 claims abstract description 24
- 108010035532 Collagen Proteins 0.000 claims abstract description 24
- 229920001436 collagen Polymers 0.000 claims abstract description 24
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 16
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 16
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 16
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 16
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 14
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 13
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 3
- 230000007365 immunoregulation Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 206010052428 Wound Diseases 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 13
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 206010008323 cervicitis Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 201000003988 chronic cervicitis Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 201000003505 cervical polyp Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于修复宫颈糜烂的凝胶及其制备方法,解决了目前治疗宫颈糜烂的方法均存在弊端的问题,本发明包括以下质量浓度的各组分:二氧化硅为0.05%‑0.5%,胶原蛋白为0.25%‑1%,羧甲基纤维素为0.5‑5%;所述的二氧化硅为经硫酸铬溶液浸泡后离心分离的二氧化硅粉末,所述的胶原蛋白为经乙酸溶液搅拌溶解的未水解胶原蛋白。本技术方案通过对二氧化硅粉末的处理,使其具有特定的免疫调节能力,再将其加入一种凝胶体系后用于提升机体的自身修复性能,从而达到快速修复难愈性的炎性宫颈糜烂的目的。各组分合理搭配,制备过程极大保留有益物质,各组分相互促进。
Description
技术领域
本发明涉及生物医药领域,尤其涉及一种用于修复宫颈糜烂的凝胶及其制备方法。
背景技术
慢性宫颈炎是常见的妇科疾病,好发于有性生活的女性。近年来其发病率越来越高。慢性宫颈炎的最主要类型是宫颈糜烂,伴有宫颈口脓液堵塞、宫颈息肉、宫颈肥大以及宫颈糜烂等,主要临床症状表现为排尿困难、腰腹部疼痛、阴道出血,白带异常等症状。慢性宫颈炎治疗期较长且病情易反复,对患者的心理造成极大的折磨。随着医疗科技的发展,发现该病的发生还与部分病毒有着密切联系,例如人乳头瘤病毒、单纯疱疹病毒等,随着疾病的发展,患者极有可能患宫颈癌,生命安全受到巨大的威胁。
目前治疗宫颈炎的方案为物理治疗、药物治疗与手术治疗物理治疗如括波姆光是利用正常组织与病灶组织之间不同的能量光波的选择吸收性不同,同时受红外线、光辐射的光热效应影响,会加快局部病灶组织发生变性、凝固、坏死等,可促进创面的愈合,发挥治疗效果。药物治疗分为全身治疗与局部治疗,全身治疗通常给予克林霉素、青霉素、红霉素等进行治疗。药物局部治疗则通常采用的是具有抑菌消炎、去腐生肌的中药治疗,通常是将药物制成凝胶或乳膏进行宫颈部位涂抹,也可制成汤剂,进行灌洗。手术治疗通常采用Leep刀治疗,患者一般是药物/物理治疗效果不佳、宫颈糜烂严重、宫颈息肉较大的患者。Leep刀所选用的金属丝,可阻抗病灶组织,如果病灶组织与传导的高频电波接触时,病灶组织吸收了热量之后,会被迅速的切割,周围边缘的组织并不会遭到破坏,可最大限度的保留患者的生育功能。
虽然临床上治疗慢性宫颈炎,尤其是慢性宫颈炎导致的宫颈糜烂已经有很多的治疗手段。但还是存在不足,如物理治疗和药物治疗对炎性糜烂较重的患者通常治疗效果不佳,或治疗周期很长,且导致患者的依从性较差,进一步影响疗效。手术治疗虽然对严重的宫颈糜烂或息肉有效,但仍有导致创伤以及瘢痕的风险,影响生育等功能。因此临床上需要开发一种新的治疗方法,对严重的宫颈炎性糜烂进行有效治疗。
发明内容
本发明为了解决上述不足,提供了一种用于修复宫颈糜烂的凝胶及其制备方法,达到快速修复难愈性的炎性宫颈糜烂的目的。
本发明的上述目的通过以下的技术方案来实现:一种用于修复宫颈糜烂的凝胶,包括以下质量浓度的各组分:二氧化硅为0.05%-0.5%,胶原蛋白为0.25%-1%,羧甲基纤维素为0.5-5%;
所述的二氧化硅为经硫酸铬溶液浸泡后离心分离的二氧化硅粉末,所述的胶原蛋白为经乙酸溶液搅拌溶解的未水解胶原蛋白。
本发明中采用的二氧化硅粉末是一类非常安全的生物材料,含二氧化硅的材料已经在骨材料领域得到了广泛的应用,硅元素是人体中一种微量元素,且硅元素在人体中的吸收度非常低,各类生理学与病理学评价也显示二氧化硅不会对人体产生任何的细胞毒性与生殖毒性。除安全性外,硅元素本身作为一种特殊的微量元素,具有促进血管内皮细胞迁移、聚集、增殖的作用,同时促进其细胞分泌VEGF、bFGF、FGF等生长因子的作用,这些因子的作用能促进创面血管化与上皮细胞增殖,从而加快糜烂创面的愈合。
血液中含有大量的白细胞,具有分泌各类因子的作用,在不同的条件刺激下,白细胞既能分泌促进炎症的因子,也能分泌抑制炎症的因子。利用血液中特定的因子进行不同的疾病治疗,包括促进创面愈合已经有很多报道。利用硫酸铬溶液处理的玻璃珠,会在玻璃珠表面产生特定的结构,当将这些被硫酸铬处理过的的玻璃珠与外周血孵育后,可以促进外周血中的白细胞分泌大量的IL-1Ra,IL-4、IL-10等抗炎因子,可抑制组织炎症。玻璃珠中的一种主要成分是二氧化硅,本发明人研究发现不采用玻璃珠,而采用二氧化硅粉末,在被硫酸铬处理后,当与外周血孵育后同样能促进白细胞分泌大量的抗炎因子,且分泌量远高于玻璃珠。宫颈糜烂因为是暴露创面,上皮溃烂处也会渗出血液,将适量的处理过的二氧化硅分散在凝胶体系中接触创面,可在创面部位直接刺激抗炎因子的分泌,缓解、抑制宫颈面的炎性环境,促进创面快速愈合。
在创伤发生的初期,组织会分泌一定量的蛋白酶。蛋白酶作用在血管的尖端,可促进血管的生长,同时蛋白酶还能帮助组织重塑并移除坏死的组织。但在慢性溃疡创面中,蛋白酶会过度分泌,过度分泌的蛋白酶会分解再生修复相关的生长因子,抑制新生血管,破坏新生组织,成为了阻碍创面愈合的关键因素。胶原蛋白是人体中含量最高的蛋白质,是细胞外基质的最主要组成成分,作为细胞外基质蛋白,胶原可以促进创面的愈合,已被临床修复类产品广泛引用了。同时未水解的胶原蛋白具有中和创面中过度分泌的蛋白酶的作用,从而保护创面愈合的相关生长因子(如FGF、VEGF、PDGF)以及新生的上皮组织,但水解的胶原蛋白不具有该功能。因此本发明将结构、功能完整的胶原蛋白作为敷料的重要组成成分,与二氧化硅协同发生作用,促进宫颈创面的修复,同时本发明中的工艺,最后步骤需要进行120℃的灭菌处理,该热作用对胶原蛋白具有轻微的交联作用,能使胶原蛋白更稳定的发挥作用。
羧甲基纤维素是一类应用非常广泛的生物材料,生物相容性好,可制备成凝胶敷料。羧甲基纤维素制备成的皮肤类的敷料能为创面提供安全的湿性环境,有利于低氧环境形成,促进毛细血管生成,利于坏死组织的清除,可形成半固体凝胶吸收渗出物,同时可捕捉聚集生长因子,加快创面愈合,可促进巨噬细胞、血小板、成纤维细胞和中性粒细胞释放各种生长因子,而且还可调节巨噬细胞增生。除用于皮肤创面外,用于阴道与宫颈相关的创面,羧甲基纤维素的这些特性仍然能够维持,因此本发明将羧甲基纤维素作为成凝胶体系的基础成分。
作为优选,所述的二氧化硅粉末平均直径小于100微米。
作为优选,所述的乙酸溶液的质量浓度为0.05%-0.5%。
一种用于修复宫颈糜烂的凝胶的制备方法:
a、取一定量的二氧化硅粉末,然后浸泡在0.5%-5%的硫酸铬溶液中10-60分钟,离心收集二氧化硅粉末后,用无菌去离子水清洗,然后置于烘箱中干燥;
b、用质量比浓度为0.1%-0.5%的乙酸溶液在2-8℃条件下搅拌溶解未水解的胶原蛋白,使胶原蛋白的浓度达到0.1%-2%;
c、按照1%-10%的质量比称取羧甲基纤维素置于无菌去离子水中,高温搅拌至成为凝胶;
d、将二氧化硅粉末、乙酸溶液溶解的胶原蛋白和羧甲基纤维素凝胶在4℃条件下混合并搅拌均匀,形成一个复合物凝胶;
e、将复合的凝胶,分装在密封的推注器中,然后进行120℃的加热处理20-60分钟,冷却后待用。
一种用于修复宫颈糜烂的凝胶及其制备方法,通过对二氧化硅粉末的处理,使其具有特定的免疫调节能力,再将其加入一种凝胶体系后用于提升机体的自身修复性能,从而达到快速修复难愈性的炎性宫颈糜烂的目的。各组分合理搭配,制备过程极大保留有益物质,各组分相互促进。
附图说明
图1是本发明临床使用案例宫颈修复参考图;
图2是本发明另一临床使用案例宫颈修复参考图;
图3是本发明另一临床使用案例宫颈修复参考图;
图4是本发明另一临床使用案例宫颈修复参考图。
具体实施方式
下面结合实施例对本发明进一步详述。
实施例1
一种用于修复宫颈糜烂的凝胶及其制备方法,取平均直径为50微米的二氧化硅粉末,加入到1%的硫酸铬溶液中,在室温下匀速搅拌使得硫酸铬充分浸没、接触二氧化硅粉末;
浸泡30分钟后,过滤收集二氧化硅分泌,并用去离子水清洗5遍,然后将二氧化硅粉末置于80℃烘箱中干燥备用;
取未水解的小牛皮I型胶原蛋白,用0.2%的乙酸溶液在4℃条件下搅拌溶解胶原蛋白,直至全部溶解,使胶原蛋白质量比浓度为0.5%,备用;
配制质量比浓度为3%的羧甲基纤维素,在80℃条件下充分搅拌,形成均匀的凝胶。
待羧甲基纤维素凝胶温度下降到4℃后,将胶原蛋白乙酸溶液与其等浓度混匀,并加入硫酸铬处理后的二氧化硅粉末,在4℃条件下充分搅拌均匀,最后使整个体系中羧甲基纤维素的质量比浓度为1.5%,胶原蛋白的质量比浓度为0.25%,二氧化硅的质量比浓度为0.1%,乙酸的质量比浓度0.1%。
将该复合物凝胶分装在密封的阴道推注器中,每支推注器中灌装2克的凝胶产品,然后在120℃的湿热条件下进行高温灭菌处理40分钟。
给炎性宫颈糜烂的患者使用,在控制好阴道病原微生物的条件下使用本产品,每天一支,连续使用,经期停用,使用2个月可高效修复炎性宫颈糜烂,具体案例修复效果见附图1-4。
在本发明权利要求中各组分质量浓度范围内的产品均可以产生相应效果,实施例不再一一举例。
Claims (4)
1.一种用于修复宫颈糜烂的凝胶,其特征在于,包括以下质量浓度的各组分:二氧化硅为0.05%-0.5%,胶原蛋白为0.25%-1%,羧甲基纤维素为0.5-5%;
所述的二氧化硅为经硫酸铬溶液浸泡后离心分离的二氧化硅粉末,所述的胶原蛋白为经乙酸溶液搅拌溶解的未水解胶原蛋白。
2.根据权利要求1所述的一种用于修复宫颈糜烂的凝胶,其特征在于,所述的二氧化硅粉末平均直径小于100微米。
3.根据权利要求1所述的一种用于修复宫颈糜烂的凝胶,其特征在于,所述的乙酸溶液的质量浓度为0.05%-0.5%。
4.根据权利要求1或2或3所述的一种用于修复宫颈糜烂的凝胶的制备方法,其特征在于:
a、取一定量的二氧化硅粉末,然后浸泡在0.5%-5%的硫酸铬溶液中10-60分钟,离心收集二氧化硅粉末后,用无菌去离子水清洗,然后置于烘箱中干燥;
b、用质量比浓度为0.1%-0.5%的乙酸溶液在2-8℃条件下搅拌溶解未水解的胶原蛋白,使胶原蛋白的浓度达到0.1%-2%;
c、按照1%-10%的质量比称取羧甲基纤维素置于无菌去离子水中,高温搅拌至成为凝胶;
d、将二氧化硅粉末、乙酸溶液溶解的胶原蛋白和羧甲基纤维素凝胶在4℃条件下混合并搅拌均匀,形成一个复合物凝胶;
e、将复合的凝胶,分装在密封的推注器中,然后进行120℃的加热处理20-60分钟,冷却后待用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011522876.4A CN112603991A (zh) | 2020-12-22 | 2020-12-22 | 一种用于修复宫颈糜烂的凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011522876.4A CN112603991A (zh) | 2020-12-22 | 2020-12-22 | 一种用于修复宫颈糜烂的凝胶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112603991A true CN112603991A (zh) | 2021-04-06 |
Family
ID=75244326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011522876.4A Pending CN112603991A (zh) | 2020-12-22 | 2020-12-22 | 一种用于修复宫颈糜烂的凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112603991A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101829144A (zh) * | 2010-05-06 | 2010-09-15 | 黄小英 | 二氧化硅超微粉末的应用及一种用于治疗子宫颈炎的药物 |
CN107596075A (zh) * | 2017-10-25 | 2018-01-19 | 桂林浩新科技服务有限公司 | 一种治疗宫颈炎的药物组合物配方及用途 |
US20180303866A1 (en) * | 2017-04-20 | 2018-10-25 | Zoetis Services Llc | Veterinary compositions for use in treating mastitis, and associated methods |
-
2020
- 2020-12-22 CN CN202011522876.4A patent/CN112603991A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101829144A (zh) * | 2010-05-06 | 2010-09-15 | 黄小英 | 二氧化硅超微粉末的应用及一种用于治疗子宫颈炎的药物 |
US20180303866A1 (en) * | 2017-04-20 | 2018-10-25 | Zoetis Services Llc | Veterinary compositions for use in treating mastitis, and associated methods |
CN107596075A (zh) * | 2017-10-25 | 2018-01-19 | 桂林浩新科技服务有限公司 | 一种治疗宫颈炎的药物组合物配方及用途 |
Non-Patent Citations (1)
Title |
---|
姚卉等: "胶原蛋白海绵治疗宫颈糜烂临床疗效观察", 《包头医学》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Banwell | Topical negative pressure therapy in wound care | |
Xie et al. | Transparent photothermal hydrogels for wound visualization and accelerated healing | |
WO2007033591A1 (fr) | Substance active pour prothese en cas de blessures | |
CN112933214A (zh) | 一种促进伤口愈合的组合物 | |
CN112603991A (zh) | 一种用于修复宫颈糜烂的凝胶及其制备方法 | |
CN101380349B (zh) | 一种烧伤、烫伤药膏 | |
CN103585347A (zh) | 一种治疗烧烫伤的中药组合物及其制备方法 | |
AU2020103805A4 (en) | A traditional chinese herbal ointment for promoting wound healing and reducing scar formation and preparation method thereof | |
CN1037152C (zh) | 生肌愈皮膏 | |
CN106562953A (zh) | 羟基红花黄色素a在制备治疗糖尿病足溃疡的药物中的应用、药物及药物制备方法 | |
Yang et al. | HydrofiberTM dressing with silver in wound healing after surgery for anal fistula | |
RU2741931C1 (ru) | Способ лечения инфицированных ран у крыс на фоне длительно текущего сахарного диабета | |
CN111840633B (zh) | 一种皮肤修复膜及其制备方法 | |
Lu et al. | Effect of calcium alginate dressing on the cytokine contents, collagen synthesis-degradation balance and apoptosis gene expression in the wound after perianal abscess surgery | |
RU2446784C1 (ru) | Способ местного лечения фолликулитов и фурункулов | |
RU2806724C1 (ru) | Ранозаживляющая пленка пролонгированного действия | |
RU2793743C1 (ru) | Способ лечения ран кожи и мягких тканей с помощью раневого покрытия на основе бактериальной целлюлозы | |
Dhamasari et al. | Stevens-Johnson Syndrome (SSJ) and Toxic Epidermal Necrolysis (TEN) | |
WO2021098887A1 (zh) | 可穿戴柔性超声尿道瘢痕治疗仪 | |
RU2803777C1 (ru) | Восковая мазь "ВОСКОСАП" | |
Wan et al. | Observation on the effects of recombinant bovine basic fibroblast growth factor gel on wound repair after cervical LEEP | |
CN114558067A (zh) | 妇科止血生肌散及应用 | |
CN118267513A (zh) | 一种愈合粉组合物及其制备方法 | |
RU2712213C1 (ru) | Перевязочное средство из пуха початков рогоза, обработанного 1% спиртовым раствором бриллиантового зеленого | |
CN113546212A (zh) | 一种具有宫颈术后止血功能且防止感染的液体敷料及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210406 |